Press release
Deadline on July 20, 2020, coming up in Lawsuit filed for Investors in shares of CytomX Therapeutics, Inc. (NASDAQ: CTMX)
A Deadline is coming up on July 20, 2020 in the lawsuit for certain investors in CytomX Therapeutics, Inc. (NASDAQ: CTMX).
Investors who purchased shares of CytomX Therapeutics, Inc. (NASDAQ: CTMX) have certain options and there are strict and short deadlines running. Deadline: July 20, 2020. NASDAQ: CTMX stockholders should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
According to the complaint filed in the U.S. District Court for the Northern District of California the plaintiff alleges on behalf of purchasers of CytomX Therapeutics, Inc. (NASDAQ: CTMX common shares between May 17, 2018, and May 13, 2020, that the defendants violated Federal Securities Laws.
More specifically, the plaintiff claims that between May 17, 2018, and May 13, 2020, the defendants failed to disclose to investors that CytomX had downplayed issues with CX-072’s efficacy observed in the PROCLAIM-CX-072 clinical program, that CytomX had similarly downplayed issues with CX-2009’s efficacy and safety observed in the PROCLAIM-CX-2009 clinical program, and that as a result, the Company’s public statements were materially false and misleading at all relevant times.
Those who purchased shares of CytomX Therapeutics, Inc. (NASDAQ: CTMX) have certain options and should contact the Shareholders Foundation.
Media Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com
About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities class actions, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Deadline on July 20, 2020, coming up in Lawsuit filed for Investors in shares of CytomX Therapeutics, Inc. (NASDAQ: CTMX) here
News-ID: 2082509 • Views: …
More Releases from Shareholders Foundation
ALERT: Lawsuit filed for Investors who SOLD shares of Sina Corporation (formerly …
An investor, who sold shares of Sina Corporation (formerly NASDAQ: SINA) in the merger between Seina Corporation and TuSimple Holdings, Inc, filed a lawsuit over alleged violations of Federal Securities Laws by Sina Corporation (formerly NASDAQ: SINA in connection with certain allegedly false and misleading statements made.
If you sold a significant amount of shares of Sina Corporation (formerly NASDAQ: SINA) between October 13, 2020 and March 22, 2021, you have…
Lawsuit Alert: Investors who lost money with shares of Fluor Corporation (NYSE: …
An investor, who purchased shares of Fluor Corporation (NYSE: FLR), filed a lawsuit alleged violations of Federal Securities Laws by Fluor Corporation in connection with certain allegedly false and misleading statements.
Investors who purchased shares of Fluor Corporation (NYSE: FLR) have certain options and for certain investors are short and strict deadlines running. Deadline: November 14, 2025. NYSE: FLR investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779…
Investigation announced for Long-Term Investors in shares of Sable Offshore Corp …
An investigation was announced for long-term investors in shares of Sable Offshore Corp. (NYSE: SOC) concerning potential breaches of fiduciary duties by certain directors of Sable Offshore Corp.
Investors who are current long term investors in Sable Offshore Corp. (NYSE: SOC) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm for current long term investors in…
Lawsuit filed for Investors who lost money with shares of Lantheus Holdings, Inc …
An investor, who purchased shares of Lantheus Holdings, Inc. (NASDAQ: LNTH), filed a lawsuit over alleged violations of Federal Securities Laws by Lantheus Holdings, Inc. in connection with certain allegedly false and misleading statements.
Investors who purchased shares of Lantheus Holdings, Inc. (NASDAQ: LNTH) have certain options and for certain investors are short and strict deadlines running. Deadline: November 10, 2025. NASDAQ: LNTH investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com…
More Releases for CytomX
HER2 Negative Breast Cancer Pipeline 2025: FDA Updates, Therapy Innovations, and …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, HER2 Negative Breast Cancer pipeline constitutes 70+ key companies continuously working towards developing 75+ HER2 Negative Breast Cancer treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
"HER2 Negative Breast Cancer Pipeline Insight, 2025" [https://www.delveinsight.com/sample-request/her2-negative-breast-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=promotion&utm_campaign=gpr] report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the HER2…
TROP2 Targeted Cancer Therapy Market Top Companies Study - Amunix, BiOneCure The …
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global TROP2 (Trophoblast Cell-surface Antigen 2) Targeted Cancer Therapy Market- (By Application (Breast Cancer, Prostate Cancer, Lung Cancer, Colorectal Cancer, Pancreatic Cancer, and Others)), By Region, Trends, Industry Competition Analysis, Revenue and Forecast To 2034."
According to the latest research by InsightAce Analytic, the Global TROP2 (Trophoblast Cell-surface Antigen 2) Targeted Cancer Therapy Market is expected to…
TROP2 Targeted Cancer Therapy Market Key Players Analysis - Amunix, BiOneCure Th …
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global TROP2 (Trophoblast Cell-surface Antigen 2) Targeted Cancer Therapy Market- (By Application (Breast Cancer, Prostate Cancer, Lung Cancer, Colorectal Cancer, Pancreatic Cancer, and Others)), By Region, Trends, Industry Competition Analysis, Revenue and Forecast To 2034."
According to the latest research by InsightAce Analytic, the Global TROP2 (Trophoblast Cell-surface Antigen 2) Targeted Cancer Therapy Market is expected to…
HER2 Negative Breast Cancer Pipeline 2025: Therapies, MOA Insights, and Key Clin …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, HER2 Negative Breast Cancer pipeline constitutes 70+ key companies continuously working towards developing 85+ HER2 Negative Breast Cancer treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
"HER2 Negative Breast Cancer Pipeline Insight, 2025 [https://www.delveinsight.com/sample-request/her2-negative-breast-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=promotion&utm_campaign=gpr]" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the HER2…
TROP2 Targeted Cancer Therapy Market Top Companies Study - Amunix, BiOneCure The …
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global TROP2 (Trophoblast Cell-surface Antigen 2) Targeted Cancer Therapy Market- (By Application (Breast Cancer, Prostate Cancer, Lung Cancer, Colorectal Cancer, Pancreatic Cancer, and Others)), By Region, Trends, Industry Competition Analysis, Revenue and Forecast To 2031."
According to the latest research by InsightAce Analytic, the Global TROP2 (Trophoblast Cell-surface Antigen 2) Targeted Cancer Therapy Market is expected to…
Investigation announced for Long-Term Investors in CytomX Therapeutics, Inc. (NA …
An investigation was announced concerning potential breaches of fiduciary duties by certain directors of CytomX Therapeutics, Inc.
Investors who are current long term investors in CytomX Therapeutics, Inc. (NASDAQ: CTMX) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm for current long term investors inNASDAQ: CTMX stocks follows a lawsuit filed against CytomX Therapeutics, Inc. over…
